title: [Curative effect of pemetrexed on the treatment of relapsed primary central nervous system lymphoma].
abstract: OBJECTIVE
  To explore the efficacy and safety of pemetrexed in the treatment of relapsed primary central nervous system lymphoma (PCNSL).
  
  
  METHODS
  Seven cases with relapsed PCNSL admitted in our hospital between August 2012 and August 2013 were retrospectively reviewed.
  
  
  RESULTS
  Of the 7 relapsed cases, ectopic recurrence occurred in 3, in situ recurrence in 3 and leptomeningeal metastasis in 1. Patients with relapsed PCNSL were administered with high-dose pemetrexed (900 mg/m²) once for every 3 weeks and supplemented with folic acid and vitamin B₁₂. Complete remission was obtained in 2 patients, partial remission in 3 patients and progressive disease in 2. The overall response rate was 71.4% (5/7). The main adverse reactions were myelosuppression and gastrointestinal reaction.
  
  
  CONCLUSIONS
  Treatment of relapsed PCNSL is difficult, and its prognosis is very poor. Pemetrexed therapy is a meaningful trial.
authors.affiliation: Department of Neurosurgery, Shandong Cancer Hospital & Institute, Shandong Academy of Medical Sciences, Jinan 250117, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Neurosurgery, Shandong Cancer Hospital & Institute, Shandong Academy of Medical Sciences, Jinan 250117, China.
authors.forename: Xiuhua
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Neurosurgery, Shandong Cancer Hospital & Institute, Shandong Academy of Medical Sciences, Jinan 250117, China.
authors.forename: Yu'e
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Department of Neurosurgery, Shandong Cancer Hospital & Institute, Shandong Academy of Medical Sciences, Jinan 250117, China.
authors.forename: Rongjie
authors.initials: R
authors.lastname: Tao
authors.affiliation: Department of Neurosurgery, Shandong Cancer Hospital & Institute, Shandong Academy of Medical Sciences, Jinan 250117, China.
authors.forename: Yufang
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: Department of Neurosurgery, Shandong Cancer Hospital & Institute, Shandong Academy of Medical Sciences, Jinan 250117, China.
authors.forename: Rongrong
authors.initials: R
authors.lastname: Zhao
authors.affiliation: Department of Neurosurgery, Shandong Cancer Hospital & Institute, Shandong Academy of Medical Sciences, Jinan 250117, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Xu
mesh_terms: D000328:Adult; D000368:Aged; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005971:Glutamates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006147:Guanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D000068437:Pemetrexed; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine